177 related articles for article (PubMed ID: 36512927)
21. Inhibition of Cell Proliferation and Growth of Pancreatic Cancer by Silencing of Carbohydrate Sulfotransferase 15 In Vitro and in a Xenograft Model.
Takakura K; Shibazaki Y; Yoneyama H; Fujii M; Hashiguchi T; Ito Z; Kajihara M; Misawa T; Homma S; Ohkusa T; Koido S
PLoS One; 2015; 10(12):e0142981. PubMed ID: 26642349
[TBL] [Abstract][Full Text] [Related]
22. Small Nucleolar Noncoding RNA SNORA23, Up-Regulated in Human Pancreatic Ductal Adenocarcinoma, Regulates Expression of Spectrin Repeat-Containing Nuclear Envelope 2 to Promote Growth and Metastasis of Xenograft Tumors in Mice.
Cui L; Nakano K; Obchoei S; Setoguchi K; Matsumoto M; Yamamoto T; Obika S; Shimada K; Hiraoka N
Gastroenterology; 2017 Jul; 153(1):292-306.e2. PubMed ID: 28390868
[TBL] [Abstract][Full Text] [Related]
23. Precise Photodynamic Therapy by Midkine Nanobody-Engineered Nanoparticles Remodels the Microenvironment of Pancreatic Ductal Adenocarcinoma and Potentiates the Immunotherapy.
Qu C; Yuan H; Tian M; Zhang X; Xia P; Shi G; Hou R; Li J; Jiang H; Yang Z; Chen T; Li Z; Wang J; Yuan Y
ACS Nano; 2024 Feb; 18(5):4019-4037. PubMed ID: 38253029
[TBL] [Abstract][Full Text] [Related]
24. BET bromodomain inhibitors block growth of pancreatic cancer cells in three-dimensional collagen.
Sahai V; Kumar K; Knab LM; Chow CR; Raza SS; Bentrem DJ; Ebine K; Munshi HG
Mol Cancer Ther; 2014 Jul; 13(7):1907-17. PubMed ID: 24807963
[TBL] [Abstract][Full Text] [Related]
25. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer.
Huang J; Chen P; Liu K; Liu J; Zhou B; Wu R; Peng Q; Liu ZX; Li C; Kroemer G; Lotze M; Zeh H; Kang R; Tang D
Gut; 2021 May; 70(5):890-899. PubMed ID: 32816920
[TBL] [Abstract][Full Text] [Related]
26. ProNGF siRNA inhibits cell proliferation and invasion of pancreatic cancer cells and promotes anoikis.
Xu J; Song J; Yang X; Guo J; Wang T; Zhuo W
Biomed Pharmacother; 2019 Mar; 111():1066-1073. PubMed ID: 30841420
[TBL] [Abstract][Full Text] [Related]
27. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
[TBL] [Abstract][Full Text] [Related]
28. Reversibly Stabilized Polycation Nanoparticles for Combination Treatment of Early- and Late-Stage Metastatic Breast Cancer.
Chen G; Wang Y; Wu P; Zhou Y; Yu F; Zhu C; Li Z; Hang Y; Wang K; Li J; Sun M; Oupicky D
ACS Nano; 2018 Jul; 12(7):6620-6636. PubMed ID: 29985577
[TBL] [Abstract][Full Text] [Related]
29. Combined MEK and STAT3 Inhibition Uncovers Stromal Plasticity by Enriching for Cancer-Associated Fibroblasts With Mesenchymal Stem Cell-Like Features to Overcome Immunotherapy Resistance in Pancreatic Cancer.
Datta J; Dai X; Bianchi A; De Castro Silva I; Mehra S; Garrido VT; Lamichhane P; Singh SP; Zhou Z; Dosch AR; Messaggio F; Ban Y; Umland O; Hosein PJ; Nagathihalli NS; Merchant NB
Gastroenterology; 2022 Dec; 163(6):1593-1612. PubMed ID: 35948109
[TBL] [Abstract][Full Text] [Related]
30. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
[TBL] [Abstract][Full Text] [Related]
31. Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models.
Mahajan UM; Li Q; Alnatsha A; Maas J; Orth M; Maier SH; Peterhansl J; Regel I; Sendler M; Wagh PR; Mishra N; Xue Y; Allawadhi P; Beyer G; Kühn JP; Marshall T; Appel B; Lämmerhirt F; Belka C; Müller S; Weiss FU; Lauber K; Lerch MM; Mayerle J
Gastroenterology; 2021 Sep; 161(3):996-1010.e1. PubMed ID: 34097885
[TBL] [Abstract][Full Text] [Related]
32. iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer.
Lo JH; Hao L; Muzumdar MD; Raghavan S; Kwon EJ; Pulver EM; Hsu F; Aguirre AJ; Wolpin BM; Fuchs CS; Hahn WC; Jacks T; Bhatia SN
Mol Cancer Ther; 2018 Nov; 17(11):2377-2388. PubMed ID: 30097486
[TBL] [Abstract][Full Text] [Related]
33. Increased Survival by Pulmonary Treatment of Established Lung Metastases with Dual STAT3/CXCR4 Inhibition by siRNA Nanoemulsions.
Li Z; Chen G; Ding L; Wang Y; Zhu C; Wang K; Li J; Sun M; Oupicky D
Mol Ther; 2019 Dec; 27(12):2100-2110. PubMed ID: 31481310
[TBL] [Abstract][Full Text] [Related]
34. Genome-wide CRISPR screen reveals PSMA6 to be an essential gene in pancreatic cancer cells.
Bakke J; Wright WC; Zamora AE; Oladimeji P; Crawford JC; Brewer CT; Autry RJ; Evans WE; Thomas PG; Chen T
BMC Cancer; 2019 Mar; 19(1):253. PubMed ID: 30898113
[TBL] [Abstract][Full Text] [Related]
35. A nanodrug simultaneously inhibits pancreatic stellate cell activation and regulatory T cell infiltration to promote the immunotherapy of pancreatic cancer.
Wang R; Hong K; Zhang Q; Cao J; Huang T; Xiao Z; Wang Y; Shuai X
Acta Biomater; 2023 Oct; 169():451-463. PubMed ID: 37572982
[TBL] [Abstract][Full Text] [Related]
36. PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer.
Ostapoff KT; Awasthi N; Cenik BK; Hinz S; Dredge K; Schwarz RE; Brekken RA
Mol Cancer Ther; 2013 Jul; 12(7):1190-201. PubMed ID: 23696215
[TBL] [Abstract][Full Text] [Related]
37. Aptamer-SH2 superbinder-based targeted therapy for pancreatic ductal adenocarcinoma.
Liu AD; Zhou J; Bi XY; Hou GQ; Li SS; Chen Q; Xu H; Cao X
Clin Transl Med; 2021 Mar; 11(3):e337. PubMed ID: 33783993
[TBL] [Abstract][Full Text] [Related]
38. Targeting Purinergic Receptor P2Y2 Prevents the Growth of Pancreatic Ductal Adenocarcinoma by Inhibiting Cancer Cell Glycolysis.
Hu LP; Zhang XX; Jiang SH; Tao LY; Li Q; Zhu LL; Yang MW; Huo YM; Jiang YS; Tian GA; Cao XY; Zhang YL; Yang Q; Yang XM; Wang YH; Li J; Xiao GG; Sun YW; Zhang ZG
Clin Cancer Res; 2019 Feb; 25(4):1318-1330. PubMed ID: 30420446
[TBL] [Abstract][Full Text] [Related]
39. Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival.
Wörmann SM; Song L; Ai J; Diakopoulos KN; Kurkowski MU; Görgülü K; Ruess D; Campbell A; Doglioni C; Jodrell D; Neesse A; Demir IE; Karpathaki AP; Barenboim M; Hagemann T; Rose-John S; Sansom O; Schmid RM; Protti MP; Lesina M; Algül H
Gastroenterology; 2016 Jul; 151(1):180-193.e12. PubMed ID: 27003603
[TBL] [Abstract][Full Text] [Related]
40. CXCL10 and CCL21 Promote Migration of Pancreatic Cancer Cells Toward Sensory Neurons and Neural Remodeling in Tumors in Mice, Associated With Pain in Patients.
Hirth M; Gandla J; Höper C; Gaida MM; Agarwal N; Simonetti M; Demir A; Xie Y; Weiss C; Michalski CW; Hackert T; Ebert MP; Kuner R
Gastroenterology; 2020 Aug; 159(2):665-681.e13. PubMed ID: 32330476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
